PRODUCT INFORMATION

LXR-623

Item No. 21117



CAS Registry No.: 875787-07-8
Formal Name: 2-[(2-chloro-4-fluorophenyl)methyl]-3-(4-fluorophenyl)-7-(trifluoromethyl)-2H-indazole
Synonym: WAY-252623
MF: $C_{21}H_{12}ClF_5N_2$
FW: 422.8
Purity: ≥98%
UV/Vis.: λ_{max}: 209, 318 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

LXR-623 is supplied as a crystalline solid. A stock solution may be made by dissolving the LXR-623 in the solvent of choice, which should be purged with an inert gas. LXR-623 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of LXR-623 in these solvents is approximately 30 mg/ml.

LXR-623 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, LXR-623 should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. LXR-623 has a solubility of approximately 0.3 mg/ml in a 1:2 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

LXR-623 is a liver X receptor (LXR) modulator that acts as a partial agonist at LXRα and a full agonist at LXRβ (IC_{50}s = 179 and 24 nM, respectively).[1,2] It is orally bioavailable and readily passes the blood-brain barrier.[1-3] LXR-623 is anti-atherogenic in animal models of atherosclerosis, showing synergistic effects when combined with simvastatin (Item Nos. 10010344 | 10010345).[1,2,4]

References

1. DiBlasio-Smith, E., Arai, M., Quinet, E.M., *et al.* Discovery and implementation of transcriptional biomarkers of synthetic LXR agonists in peripheral blood cells. *J. Transl. Med.* **6**, 59 (2008).
2. Quinet, E.M., Basso, M.D., Halpern, A.R., *et al.* LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse. *J. Lipid. Res.* **50(12)**, 2358-2370 (2009).
3. Villa, G.R., Hulce, J.J., Zanca, C., *et al.* An LXR-cholesterol axis creates a metabolic co-dependency for brain cancers. *Cancer Cell.* **30(5)**, 683-693 (2016).
4. Giannarelli, C., Cimmino, G., Connolly, T.M. , *et al.* Synergistic effect of liver X receptor activation and simvastatin on plaque regression and stabilization: An magnetic resonance imaging study in a model of advanced atherosclerosis. *Eur. Heart J.* **33(2)**, 264-273 (2012).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM